{"id":"NCT02728752","sponsor":"Octapharma","briefTitle":"Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)","officialTitle":"Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (\"ProDERM Study\")","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-27","primaryCompletion":"2019-11-05","completion":"2019-11-05","firstPosted":"2016-04-05","resultsPosted":"2021-04-21","lastUpdate":"2021-12-23"},"enrollment":95,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Dermatomyositis"],"interventions":[{"type":"DRUG","name":"Octagam 10%","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Octagam10%","type":"EXPERIMENTAL"}],"summary":"Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (\"ProDERM study\")","primaryOutcome":{"measure":"Measure the Number of Patients Who Had an Increase of â‰¥20 Points on the Total Improvement Score (TIS)","timeFrame":"At week 16","effectByArm":[{"arm":"Placebo","deltaMin":21,"sd":null},{"arm":"Octagam10%","deltaMin":37,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":37,"countries":["United States","Canada","Czechia","Germany","Hungary","Netherlands","Poland","Romania","Russia","Ukraine"]},"refs":{"pmids":["40616720","39918968","38233885","37799613","36198179","33429735"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":48},"commonTop":["Headache","Nausea","Pyrexia","Condition aggravated","Arthralgia"]}}